Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

被引:17
|
作者
Papeix, C. [1 ]
Donze, C. [2 ]
Lebrun-Frenay, C. [3 ]
机构
[1] Sorbonne Univ, Hop Pitie Salpetriere, AP HP 6, Dept Neurol,CRCSEP Paris, F-75013 Paris, France
[2] Hop St Philibert, Fac Med & Maleut Lille, Grp Hop Inst Catholique Lille, Lomme Les Lille, France
[3] Cote dAzur Univ, URC2A, CRCSEP Cote dAzur, Neurol,Hop Pasteur2,CHU Nice, Nice, France
关键词
Multiple sclerosis; Infections; Prevention; Immuno-active treatment; PLACEBO-CONTROLLED TRIAL; EPSTEIN-BARR-VIRUS; DOUBLE-BLIND; INTERFERON BETA-1A; VIRAL-INFECTIONS; OPEN-LABEL; INTRAMUSCULAR INTERFERON; ORAL TERIFLUNOMIDE; GLATIRAMER ACETATE; CONTROLLED PHASE-3;
D O I
10.1016/j.neurol.2021.04.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. - Viral, bacterial, or fungal infections are suspected of triggering multiple sclerosis (MS) and promoting relapses of the disease and are likely to be promoted by immune-active treatments. This raises questions about the infectious workup and preventive treatment of these infections prior to their initiation. Objectives. - To establish recommendations on infections and MS. Provide information to patients and healthcare professionals on the minimal infectious workup to be performed in an MS patient at diagnosis and prior to initiation of immuno- active therapy in MS. Methods. - The recommendation attempts to answer four main questions about infections and MS. The French Group for Recommendations in Multiple Sclerosis (France4MS) did a systematic review of articles from PubMed and universities databases (from January 1975 to June 2020), using the RAND/UCLA formalized consensus method. The RAND/UCLA method has been developed to synthesize the scientific literature and expert opinions on health care topics and was used for reaching a formal agreement. Twenty-three experts contributed to the detailed review and a group of 63 multidisciplinary health professionals validated the final version of 36 recommendations. Results. - It is recommended that MS patients undergo a minimal infectious workup, check their vaccination status at diagnosis, and repeat it during follow-up and before starting immunotherapy. Screening and preventive treatment of viral (group Herpes virus, HPV, JCV, HCV, HBV), bacterial (mycobacteria) and fungal (Cryptococcus) infections is recommended prior to the initiation of certain immuno-active MS therapies. Discussion and conclusions. - At diagnosis of MS and prior to the choice of therapeutic strategy, it is recommended to update the vaccination schedule of MS patients in reference to the HCSP vaccination schedule and the SFSEP recommendations. Before starting immunosuppressive treatment, it is recommended to inform patients of the risks of infections and to look for a constitutive or acquired immune deficiency. Health professionals and patients should be informed of the updated recommendations on infections and MS. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:980 / 994
页数:15
相关论文
共 50 条
  • [21] How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)
    Bigaut, Kevin
    Cohen, Mikael
    Durand-Dubief, Francoise
    Maillart, Elisabeth
    Planque, Evelyne
    Zephir, Helene
    Lebrun-Frenay, Christine
    de Seze, Jerome
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 53
  • [22] Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World
    Frau, Jessica
    Coghe, Giancarlo
    Lorefice, Lorena
    Fenu, Giuseppe
    Cocco, Eleonora
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [23] Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective
    Jakimovski, Dejan
    Weinstock-Guttman, Bianca
    Ramanathan, Murali
    Dwyer, Michael G.
    Zivadinov, Robert
    VACCINES, 2020, 8 (01)
  • [24] Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society
    Kulakowska, Alina
    Mirowska-Guzel, Dagmara
    Kalinowska, Alicja
    Bartosik-Psujek, Halina
    Brola, Waldemar
    Stasiolek, Mariusz
    Glabinski, Andrzej
    Losy, Jacek
    Potemkowski, Andrzej
    Rejdak, Konrad
    Sarzynska-Dlugosz, Iwona
    Siger, Malgorzata
    Stepien, Adam
    Wawrzyniak, Slawomir
    Zaborski, Jacek
    Zakrzewska-Pniewska, Beata
    Adamczyk-Sowa, Monika
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2024, 58 (06) : 569 - 585
  • [25] Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy
    Rosciszewska-Zukowska, Iwona
    Kulakowska, Alina
    Kalinowska, Alicja
    Bartosik-Psujek, Halina
    Mirowska-Guzel, Dagmara
    Stasiolek, Mariusz
    Zakrzewska-Pniewska, Beata
    Brola, Waldemar
    Wawrzyniak, Slawomir
    Golebiowski, Marek
    Mackiewicz, Jacek
    Kaminska-Winciorek, Grazyna
    Czarnecka, Anna M.
    Maciejczyk, Adam
    Giebel, Sebastian
    Rutkowski, Piotr
    Cybulska-Stopa, Bozena
    Adamczyk-Sowa, Monika
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2025, 59 (01) : 20 - 32
  • [26] Treatment of Multiple Sclerosis
    Anlar, Omer
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (03) : 167 - 174
  • [27] Review of methodological issues of clinical trials in multiple sclerosis
    Montalban, Xavier
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 311 : S35 - S42
  • [28] Multiple sclerosis: a practical overview for clinicians
    Rejdak, Konrad
    Jackson, Samuel
    Giovannoni, Gavin
    BRITISH MEDICAL BULLETIN, 2010, 95 (01) : 79 - 104
  • [29] Safety concerns and risk management of multiple sclerosis therapies
    Sorensen, P. Soelberg
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 (03): : 168 - 186
  • [30] Urinary tract infections in multiple sclerosis
    Phe, Veronique
    Pakzad, Mahreen
    Curtis, Carmel
    Porter, Bernadette
    Haslam, Collette
    Chataway, Jeremy
    Panicker, Jalesh N.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (07) : 855 - 861